07:08 EST Autolus Therapeutics (AUTL) sees FY26 AUCATZYL revenue $120M-$135M
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AUTL:
- Autolus Therapeutics to evaluate automated manufacturing of AUCATZYL
- Midday Fly By: SoftBank buying DigitalBridge, Verisk drops AccuLynx deal
- Needham ups Autolus target, names top pick for 2026
- Autolus Therapeutics presents data from CATULUS Phase 1 trial of obe-cel
- Autolus Therapeutics Appoints Ryan Richardson to Board